Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity. - Jung, Okkeun; Soto, Angelene; Wolfe, Andrew L.; Mahajan, Shahana S. (PLoS ONE, 2025)